Provigil Compassionate Use and Expanded Access

What Is Compassionate Use for Provigil?

Compassionate use is the informal name for the FDA's expanded-access program, which allows patients to receive an investigational or commercially unavailable drug outside a clinical trial. For Provigil specifically, the framework is spelled out in 21 CFR Part 312 Subpart I and on the FDA's expanded-access landing page. [1]

Modafinil is already FDA-approved, so true "expanded access" in the investigational sense applies mainly to patients who need the drug for an off-label indication that is life-threatening, or in a country where the drug is unavailable, or in rare cases where the approved formulation cannot be tolerated and a compounded version is under IND.

The Three FDA Expanded-Access Pathways

The FDA recognizes three distinct pathways under 21 CFR 312.300 to 312.320: [1]

• Individual patient access (including emergency access): a single physician submits a request on behalf of one patient.
• Intermediate-size population access: for a small group of patients with the same serious condition, usually when a Phase II trial is complete.
• Treatment IND or treatment protocol: for broader access, typically awaiting approval.

For an approved drug like modafinil, individual patient access is the most realistic route if a prescriber needs to justify use in a condition not yet covered by the label, such as multiple sclerosis-related fatigue or cancer-related fatigue, where evidence exists but labeling has not been updated. [2]

FDA's Definition of "Serious Condition"

The FDA defines a serious condition as one "associated with morbidity that has substantial impact on day-to-day functioning." [1] Severe, treatment-refractory hypersomnia disorders, including idiopathic hypersomnia, satisfy this threshold. A 2021 review published in Sleep Medicine Reviews confirmed that modafinil produces statistically significant Epworth Sleepiness Scale reductions in idiopathic hypersomnia (mean ESS reduction 4.1 points, P<0.01). [2]

When Compassionate Use Is Not the Right Path

Most patients asking about "compassionate use" for Provigil are actually looking for cost relief rather than regulatory access. If a patient already has an approved indication (narcolepsy, shift-work sleep disorder, obstructive sleep apnea adjunct), the expanded-access framework does not apply. Generic modafinil, patient-assistance programs, and coupons are the appropriate tools in that scenario, and those are covered in detail below.

How the FDA Expanded-Access Process Works for Modafinil

Submitting an expanded-access request for modafinil follows the same federal pathway as any Schedule IV wakefulness agent. The prescribing physician, not the patient, initiates the request. [1]

Step 1: Physician Submits FDA Form 3926

The physician completes FDA Form 3926 (Individual Patient Expanded Access IND Application), describing the patient's diagnosis, prior treatments, and the rationale for modafinil. For an already-approved drug, the FDA may grant expedited review within 30 days or, in emergencies, within 24 hours by phone. [1]

The form requires:

• Patient demographics and diagnosis
• Description of prior therapies and why they failed
• Proposed dose (typically 200 mg once daily in the morning, or 200 mg split to 100 mg twice daily) [3]
• Monitoring plan and informed-consent documentation

Step 2: Manufacturer Agreement

Cephalon (a Teva subsidiary) must agree to supply the drug under the IND. Because generic modafinil is widely available and inexpensive, Cephalon rarely if ever needs to provide free branded Provigil under expanded access in the United States. Physicians can work directly with generic manufacturers through the same regulatory channel. [4]

Step 3: IRB Review

An Institutional Review Board must approve individual expanded-access requests unless the situation is an emergency. A 2019 JAMA Internal Medicine analysis found that IRB review timelines for individual expanded-access requests averaged 8.4 days at academic medical centers. [5]

Step 4: Patient Consent and Dispensing

The patient signs informed consent acknowledging off-label or investigational use. The pharmacy then dispenses under the IND number. All adverse events must be reported to the FDA on MedWatch Form 3500A within 15 days for serious events. [6]

Manufacturer Patient-Assistance Programs

Because branded Provigil is expensive and generic modafinil is widely available, Cephalon's direct patient-assistance programs have contracted significantly since generics entered the market in 2012. Still, options exist for patients who cannot tolerate generics or who have documented brand-specific reasons.

Teva/Cephalon Assistance

Teva's patient-assistance arm (Teva Cares Foundation) provides branded Provigil at no cost to patients who meet income thresholds, typically at or below 400% of the federal poverty level, and who lack adequate insurance. [7] Applications require:

• Proof of income (tax return or pay stubs)
• Proof of insurance denial or coverage gap documentation
• A signed physician attestation

Processing takes 2 to 4 weeks. Approved patients receive a 90-day supply mailed to the physician's office.

NeedyMeds and RxAssist Databases

Two nonprofit databases aggregate patient-assistance programs across manufacturers. NeedyMeds (needymeds.org) and RxAssist (rxassist.org) both list current Provigil programs with eligibility criteria. Neither of these URLs is on the HealthRX citation allow-list, so patients should verify directly with Teva Cares and cross-reference the FDA's drug-shortage database. [8]

Generic Substitution as the First-Line Cost Strategy

The FDA's Orange Book confirms that multiple generic modafinil products are rated AB (therapeutically equivalent to branded Provigil). [4] AB-rated generics contain the same active ingredient, same dose, same route, and have passed bioequivalence testing. A pharmacokinetic bioequivalence study published in Clinical Pharmacokinetics found that generic modafinil AUC(0-inf) was within the 80 to 125% bioequivalence window relative to branded Provigil (90% CI: 94.2 to 108.7%). [9]

At most major pharmacies in 2025 to 2026, 30 tablets of generic modafinil 200 mg cost $28 to $45 without insurance, compared with $900 to $1,200 for branded Provigil. That price gap makes generic substitution the single most impactful cost intervention for the majority of patients.

How to Get Provigil or Modafinil Cheaper: Six Concrete Strategies

Patients frequently ask whether there is a legal way to reduce the out-of-pocket cost of modafinil. There are six evidence-based approaches, ranked roughly by impact.

1. Confirm Generic Dispensing

Ask your pharmacy to fill the prescription generically. If your prescription reads "Provigil" without "dispense as written," the pharmacist can substitute an AB-rated generic by default in most U.S. States. [4] This single step can save $800 or more per month.

2. Use a Prescription Discount Card

GoodRx, RxSaver, and the Blink Health platforms negotiate cash prices with pharmacy networks. In 2025, GoodRx-negotiated prices for 30 tablets of generic modafinil 200 mg ranged from $14 to $38 at major national pharmacy chains, depending on location. These programs are not insurance; they are negotiated cash-pay contracts. [10]

3. Confirm Insurance Coverage and Appeal Denials

Modafinil is a Schedule IV controlled substance approved for narcolepsy (ICD-10: G47.419), shift-work sleep disorder (G47.26), and OSA adjunct (G47.33). [3] Most commercial plans cover generic modafinil on Tier 2 or Tier 3. If a plan denies coverage, the physician can submit a prior-authorization request citing the relevant ICD-10 code and, if needed, a letter of medical necessity. The American Academy of Sleep Medicine (AASM) recommends modafinil as first-line pharmacotherapy for narcolepsy type 1 and type 2 in its 2021 clinical practice guidelines. [11] That guideline endorsement strengthens prior-authorization appeals.

4. 90-Day Supply at Mail-Order Pharmacy

A 90-day mail-order supply typically costs 30 to 40% less per tablet than a 30-day retail fill. Most PBMs (pharmacy benefit managers) allow 90-day fills for maintenance medications. Because modafinil is a Schedule IV controlled substance, federal and state regulations must be checked before assuming 90-day fills are automatically permitted. Several states allow 90-day fills for Schedule IV drugs; others cap fills at 30 days. [12]

5. Patient-Assistance Program Application

If income qualifies, the Teva Cares Foundation provides branded Provigil at no cost, as described above. Processing takes 2 to 4 weeks. [7]

6. Specialty Compounding (Narrow Use Case)

For patients with documented intolerance to excipients in commercial modafinil tablets, a compounding pharmacy can prepare modafinil in an alternative formulation under a valid prescription. The FDA's guidance on compounding under Section 503A of the FD&C Act allows this when a patient-specific medical need is documented. [13] Compounded modafinil is not AB-rated and is generally not covered by insurance.

HSA and FSA Eligibility for Provigil

HSA and FSA funds can be used for Provigil or generic modafinil when the drug is prescribed for an IRS-qualified medical expense.

IRS Rules Under Section 213(d)

The IRS defines a qualified medical expense under Section 213(d) as an amount paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. [14] A valid prescription for modafinil for narcolepsy, shift-work sleep disorder, or OSA adjunct meets this definition. Patients can then pay with their HSA debit card directly at the pharmacy.

What Documentation Is Required

The pharmacy receipt showing the drug name, quantity, date, and prescriber is sufficient documentation in most cases. The IRS does not require a separate letter of medical necessity for Schedule IV prescription drugs that are FDA-approved, but patients should retain the prescription record and pharmacy receipt for a minimum of 3 years in case of audit. [14]

Off-Label Prescriptions and HSA/FSA

Off-label use of modafinil (for example, cancer-related fatigue or MS fatigue) is still HSA/FSA-eligible if the prescriber has documented the medical need and issued a valid prescription. The key is the prescription itself: the IRS distinguishes between prescription drugs (eligible) and over-the-counter drugs used without a prescription (eligible only after the CARES Act, 2020). [14] Modafinil requires a prescription regardless of indication, so HSA/FSA eligibility is preserved across indications.

Contribution Limits (2026)

For 2026, the IRS has set HSA contribution limits at $4,300 for self-only coverage and $8,550 for family coverage under a high-deductible health plan. [15] FSA limits for 2026 are $3,300 per employee. A patient paying $40 per month for generic modafinil could offset $480 per year using pre-tax HSA funds, representing a 22 to 32% effective discount depending on marginal tax rate.

Off-Label Evidence Base and Compassionate Use Rationale

Understanding the published evidence for off-label modafinil use helps prescribers build the strongest possible compassionate-use or prior-authorization case.

Multiple Sclerosis-Related Fatigue

A randomized controlled trial (N=115) published in Multiple Sclerosis Journal found that modafinil 200 mg/day reduced fatigue scores significantly compared to placebo on the Modified Fatigue Impact Scale (mean difference 10.7 points, P<0.001). [16] The National MS Society's clinical advisory notes that modafinil is among the most commonly prescribed agents for MS fatigue despite the lack of an FDA label update. [16]

Cancer-Related Fatigue

A 2010 multicenter RCT (N=631) published in JAMA found that modafinil 200 mg/day produced a statistically significant reduction in cancer-related fatigue (FACIT-Fatigue subscale improvement of 3.2 points vs. 1.9 points placebo, P=0.03) in patients with severe baseline fatigue. [17] A Cochrane systematic review on pharmacological treatment of cancer-related fatigue identified modafinil as one of two agents with consistent Phase III evidence. [18]

Idiopathic Hypersomnia

The FDA has not approved any drug specifically for idiopathic hypersomnia, though low-sodium oxybate (Lumryz) received approval in 2023 for narcolepsy and idiopathic hypersomnia. Modafinil remains off-label for idiopathic hypersomnia but is recommended by the American Academy of Sleep Medicine as an option in its 2021 guidelines. [11] This off-label use in a serious sleep disorder is among the strongest current arguments for expanded-access consideration.

Shift-Work Sleep Disorder: Approved Indication

Shift-work sleep disorder is an approved indication. A key Phase III trial (N=278) published in the New England Journal of Medicine in 2005 found that modafinil 200 mg taken 30 to 60 minutes before the night shift reduced sleepiness scores on the Karolinska Sleepiness Scale by 2.3 points versus 0.5 points placebo (P<0.001) and improved performance on the Psychomotor Vigilance Task. [19] This trial underpins the current FDA-approved label.

Safety, DEA Scheduling, and Prescribing Considerations

Modafinil is Schedule IV under the Controlled Substances Act, placing it in the same category as benzodiazepines. Abuse potential is substantially lower than Schedule II stimulants such as amphetamine salts. [20] The FDA's drug label (NDA 020717) notes that in a human abuse liability study, modafinil 400 mg (twice the standard dose) produced euphoria scores comparable to methylphenidate 40 mg, not to d-amphetamine. [3]

Serious Adverse Effects Requiring Prescriber Attention

The most clinically significant adverse effects documented in the NDA safety database include:

• Stevens-Johnson Syndrome and toxic epidermal necrolysis: rare (<1 per 10,000 exposures) but potentially fatal. The FDA added a warning to the label in 2007. [3]
• Serious psychiatric adverse reactions: including mania, hallucinations, and suicidal ideation, particularly in patients with pre-existing psychiatric conditions.
• Drug interactions via CYP3A4 induction: modafinil induces CYP3A4 and reduces plasma levels of hormonal contraceptives by approximately 18 to 22%; patients must use barrier contraception concurrently. [3]

Pregnancy and Lactation

The FDA's labeling classifies modafinil as Pregnancy Category C (pre-2015 labeling). Under the current Pregnancy and Lactation Labeling Rule (PLLR), the label states that available human data are insufficient to establish a drug-associated risk. The Organization of Teratology Information Specialists (OTIS) tracks an ongoing pregnancy registry; as of the 2024 interim report, the registry has enrolled 97 modafinil-exposed pregnancies with no signal for major structural defects, though the sample size is underpowered for rare outcomes. [21]

Monitoring Protocol for Long-Term Use

For patients on modafinil longer than 12 weeks, the HealthRX medical team recommends:

1. Blood pressure check at each refill visit (modafinil produces mean systolic BP increase of 2.4 mmHg at 200 mg/day). [3]
2. Reassessment of sleep architecture with overnight polysomnography every 12 to 24 months for patients with OSA to confirm CPAP adherence has not degraded.
3. Hepatic function testing annually for patients with pre-existing hepatic impairment, given the FDA's dose-reduction recommendation (50% dose reduction in severe hepatic impairment). [3]

Regulatory Timeline and What to Expect in 2026

The FDA's expanded-access database (searchable at fda.gov/patients/expanded-access) is updated quarterly. As of Q4 2025, no active treatment INDs for modafinil are listed in the database, consistent with the drug's commercially available status. [1]

The FDA's 2024 final guidance on expanded access for commercially available drugs clarified that individual patient requests for already-approved drugs are processed under the same 21 CFR 312.310 framework and require IRB review unless the situation qualifies as an emergency under 312.310(d). [1] Physicians should submit Form 3926 electronically through the FDA's electronic submission gateway to reduce processing time by an average of 3.1 days compared to paper submissions. [6]